褪黑素在帕金森病治疗中的研究进展

doi:10.3969/j.issn.1004-616x.2022.01.015

摘要/Abstract

摘要： 帕金森病是一种以运动迟缓、僵硬和静息性震颤等运动症状为主的慢性神经退行性疾病，多种途径共同参与了帕金森病的病理生理过程。褪黑素（MT）是人体内天然存在的抗氧化活性物质，大量的体内、体外实验均表明褪黑素对于帕金森病具有较好的预防和治疗作用。褪黑素补充剂对帕金森病的治疗效果与其抗氧化应激、保护线粒体、抗炎、抗毒性蛋白堆积、抗凋亡以及调节自噬等功能密切相关。临床上，褪黑素已被应用于治疗帕金森病的非运动症状。本文通过对帕金森病的病理生理机制进行总结，重点阐述褪黑素用于治疗帕金森病患者快速眼动睡眠行为障碍的研究进展。

关键词: 褪黑素, 帕金森病, 氧化应激, 线粒体, 神经炎症, 快速眼动睡眠行为障碍

中图分类号:

R114

尹亚萍, 王宇, 田雨阳, 马焜, 李百祥. 褪黑素在帕金森病治疗中的研究进展[J]. 癌变·畸变·突变, 2022, 34(1): 75-78,81.

参考文献

[1] CHEN W, XU Z M, WANG G, et al. Non-motor symptoms of Parkinson's disease in China:a review of the literature[J]. Parkinsonism Relat Disord, 2012, 18(5):446-452.
[2] LIN L, DU Y Q, YUAN S T, et al. Serum melatonin is an alternative index of Parkinson's disease severity[J]. Brain Res, 2014, 1547:43-48.
[3] KUNZ D, BES F. Twenty years after:another case report of melatonin effects on REM sleep behavior disorder, using serial dopamine transporter imaging[J]. Neuropsychobiology, 2017, 76(2):100-104.
[4] SIMON D K, TANNER C M, BRUNDIN P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology[J]. Clin Geriatr Med, 2020, 36(1):1-12.
[5] LIDDELL J R, WHITE A R. Nexus between mitochondrial function, iron, copper and glutathione in Parkinson's disease[J]. Neurochem Int, 2018, 117:126-138.
[6] WU Z, GENG Y, BUIST-HOMAN M, et al. Scopoletin and umbelliferone protect hepatocytes against palmitate- and bile acid-induced cell death by reducing endoplasmic Reticulum stress and oxidative stress[J]. Toxicol Appl Pharmacol, 2021:2021Dec31;115858.
[7] SCHAPIRA A H V. Mitochondria in the aetiology and pathogenesis of Parkinson's disease[J]. Lancet Neurol, 2008, 7(1):97-109.
[8] CHEN Q Q, HAIKAL C, LI W, et al. Gut inflammation in association with pathogenesis of Parkinson's disease[J]. Front Mol Neurosci, 2019, 12:218.
[9] KLONGPANICHAPAK S, PHANSUWAN-PUJITO P, EBADI M, et al. Melatonin inhibits amphetamine-induced increase in alpha-synuclein and decrease in phosphorylated tyrosine hydroxylase in SK-N-SH cells[J]. Neurosci Lett, 2008, 436(3):309-313.
[10] HSU L J, SAGARA Y, ARROYO A, et al. Alpha-synuclein promotes mitochondrial deficit and oxidative stress[J]. Am J Pathol, 2000, 157(2):401-410.
[11] SHAMS R, BANIK N L, HAQUE A. Calpain in the cleavage of alpha-synuclein and the pathogenesis of Parkinson's disease[J]. Prog Mol Biol Transl Sci, 2019, 167:107-124.
[12] GHIO S, KAMP F, CAUCHI R, et al. Interaction of α-synuclein with biomembranes in Parkinson's disease:role of cardiolipin[J]. Prog Lipid Res, 2016, 61:73-82.
[13] TAMTAJI O R, REITER R J, ALIPOOR R, et al. Melatonin and parkinson disease:current status and future perspectives for molecular mechanisms[J]. Cell Mol Neurobiol, 2020, 40(1):15-23.
[14] MAZURSKYY A, HOWITT J. Initiation and transmission of α-synuclein pathology in Parkinson's disease[J]. Neurochem Res, 2019, 44(12):2685-2694.
[15] SRINIVASAN V, SPENCE D W, PANDI-PERUMAL S R, et al. Melatonin in mitochondrial dysfunction and related disorders[J]. Int J Alzheimers Dis, 2011, 2011:326320.
[16] SUWANJANG W, PHANSUWAN-PUJITO P, GOVITRAPONG P, et al. The protective effect of melatonin on methamphetamine-induced calpain-dependent death pathway in human neuroblastoma SH-SY₅Y cultured cells[J]. J Pineal Res, 2010, 48(2):94-101.
[17] ZAITONE S A, HAMMAD L N, FARAG N E. Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine-parkinsonian mice[J]. Pharmacol Rep, 2013, 65(5):1213-1226.
[18] DÍAZ-CASADO M E, RUSANOVA I, ARANDA P, et al. In vivo determination of mitochondrial respiration in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated zebrafish reveals the efficacy of melatonin in restoring mitochondrial normalcy[J]. Zebrafish, 2018, 15(1):15-26.
[19] TOCHARUS J, KHONTHUN C, CHONGTHAMMAKUN S, et al. Melatonin attenuates methamphetamine-induced overexpression of pro-inflammatory cytokines in microglial cell lines[J]. J Pineal Res, 2010, 48(4):347-352.
[20] ZHOU H Y, CHEANG T, SU F J, et al. Melatonin inhibits rotenone-induced SH-SY5Y cell death via the downregulation of Dynamin-Related Protein 1 expression[J]. Eur J Pharmacol, 2018, 819:58-67.
[21] DÍAZ-CASADO M E, LIMA E, GARCÍA J A, et al. Melatonin rescues zebrafish embryos from the parkinsonian phenotype restoring the parkin/PINK1/DJ-1/MUL1 network[J]. J Pineal Res, 2016, 61(1):96-107.
[22] NIRANJAN R, NATH C, SHUKLA R. The mechanism of action of MPTP-induced neuroinflammation and its modulation by melatonin in rat astrocytoma cells, C6[J]. Free Radic Res, 2010, 44(11):1304-1316.
[23] ORTIZ G G, PACHECO-MOISÉS F P, GóMEZ-RODRÍGUEZ V M, et al. Fish oil, melatonin and vitamin E attenuates midbrain cyclooxygenase-2 activity and oxidative stress after the administration of 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine[J]. Metab Brain Dis, 2013, 28(4):705-709.
[24] SCHLACHETZKI J C M, GRIMM T, SCHLACHETZKI Z, et al. Dopaminergic lesioning impairs adult hippocampal neurogenesis by distinct modification of α-synuclein[J]. J Neurosci Res, 2016, 94(1):62-73.
[25] CHANG C F, HUANG H J, LEE H C, et al. Melatonin attenuates kainic acid-induced neurotoxicity in mouse Hippocampus via inhibition of autophagy and α-synuclein aggregation[J]. J Pineal Res, 2012, 52(3):312-321.
[26] RADOGNA F, ALBERTINI M C, DE NICOLA M, et al. Melatonin promotes Bax sequestration to mitochondria reducing cell susceptibility to apoptosis via the lipoxygenase metabolite 5-hydroxyeicosatetraenoic acid[J]. Mitochondrion, 2015, 21:113-121.
[27] NOPPARAT C, PORTER J E, EBADI M, et al. The mechanism for the neuroprotective effect of melatonin against methamphetamine-induced autophagy[J]. J Pineal Res, 2010, 49(4):382-389.
[28] KONGSUPHOL P, MUKDA S, NOPPARAT C, et al. Melatonin attenuates methamphetamine-induced deactivation of the mammalian target of rapamycin signaling to induce autophagy in SK-N-SH cells[J]. J Pineal Res, 2009, 46(2):199-206.
[29] SU L Y, LI H, LV L, et al. Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5-mediated autophagy and SNCA/α-synuclein aggregation[J]. Autophagy, 2015, 11(10):1745-1759.
[30] KASHIHARA K, NOMURA T, MAEDA T, et al. Beneficial effects of ramelteon on rapid eye movement sleep behavior disorder associated with Parkinson's disease-results of a multicenter open trial[J]. Intern Med, 2016, 55(3):231-236.
[31] GILAT M, JACKSON A C, MARSHALL N S, et al. Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease:a randomised controlled trial[J]. Mov Disord, 2020, 35(2):344-349.